MedPath
HSA Approval

CILODEX OTIC SUSPENSION

SIN13199P

CILODEX OTIC SUSPENSION

CILODEX OTIC SUSPENSION

April 18, 2006

NOVARTIS (SINGAPORE) PTE LTD

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD
Licence HolderNOVARTIS (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

SOLUTION

**4 Dosage regimen and administration** **Dosage regimen** **Acute Otitis Media in pediatric patients with tympanostomy tubes:** 4 drops twice daily (BID) in the affected ear(s) for 7 days. **Special populations** **Renal and hepatic impairment** When using Cilodex® Otic in patients with renal or hepatic impairment, dose adjustment is not necessary. **Pediatric patients** The safety and efficacy of Cilodex® Otic in pediatric patients below 6 months has not been established. **Method of administration** - For otic use only. - The bottle must be shaken well before use. - To avoid contamination, the dropper tip should not touch the ear or any other surface. - The suspension should be warmed by holding the bottle in the hand for 1–2 minutes to avoid any unpleasant sensation which may result from the instillation of a cold suspension. - The patient should lie with the affected ear upward, and then the drops should be instilled. The tragus should then be pumped 5 times by pushing inward to facilitate penetration of the drops into the middle ear. This position should be maintained for 60 seconds.

AURICULAR (OTIC)

Medical Information

**3 Indications** **Otic use** Cilodex® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute otitis media in pediatric patients (age 6 months and older) with tympanostomy tubes (AOMT) due to _Staphylococcus aureus_, _Streptococcus pneumoniae_, _Haemophilus influenzae_, _Moraxella catarrhalis_, and _Pseudomonas aeruginosa_.

**5 Contraindications** - Hypersensitivity to the active substance, any of the excipients or other quinolones. - Viral, fungal, and untreated parasitic otic infections.

J01MA02

ciprofloxacin

Manufacturer Information

NOVARTIS (SINGAPORE) PTE LTD

Alcon Laboratories Inc

Active Ingredients

DEXAMETHASONE

0.1%

Dexamethasone

CIPROFLOXACIN HYDROCHLORIDE EQV TO CIPROFLOXACIN

0.3%

Ciprofloxacin

Documents

Package Inserts

Cilodex Otic Suspension PI.pdf

Approved: August 3, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.